Table 4.

Changes in Inflammatory Parameters After 6 to 8 Weeks of Treatment but Before Endotoxin

	Randomization	Before LPS	Absolute Δ	P*
TNF-α, pg/mL
Fenofibrate	1.2±0.5	1.1±0.4	−0.1±0.3	>0.99†
Placebo	1.3±0.8	1.5±1.2	0.2±1.1
IL-6, pg/mL
Fenofibrate	1.1±0.5	2.0±0.7	0.9±0.7	0.0028†
Placebo	1.2±0.5	3.6±2.0	2.4±1.7
MCP, pg/mL
Fenofibrate	144.1±49.6	140.2±33.6	−3.8±42.2	0.66†
Placebo	146.5±36.3	147.4±33.6	0.9±21.5
CRP, mg/L
Fenofibrate	1.2±1.6	0.8±1.0	−0.4±1.5	0.36
Placebo	0.8±1.4	0.8±0.9	−0.02±1.1
Serum amyloid A, mg/L
Fenofibrate	4.2±3.9	3.1±0.8	−1.1±3.9	0.66†
Placebo	4.2±3.4	3.7±2.1	−0.4±1.6

Values are given as mean±standard deviation. LPS indicates lipopolysaccharide; MCP, monocyte chemotactic protein; and CRP, C-reactive protein.

^*P values obtained from 2-sided Student t test comparing absolute change from baseline to pre-LPS by treatment group.

^†Violated assumptions of homogeneity of variances using Levene test; P value obtained from Mann-Whitney U nonparametric test.